This week on HealthCentral, I'm looking at good news about Biologics and the systemic impact of RA:
"It’s called the mortality gap. And none of us like to think about it.
The average life expectancy of people with RA is 10 years less than the general population. RA is a systemic disease that affects not just our joints, but also our internal organs. The mortality gap exists because the systemic inflammation of RA leads to a higher incidence of heart attack and stroke.
But there's good news. A few weeks ago at the 2012 meeting of the European League Against Rheumatism (EULAR) in Berlin, researchers presented a paper showing a dramatic reduction in heart attacks in people taking anti-TNF medication, such as Enbrel, Humira and Remicade."
The rest of the post is here.